CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients

Autoantibody-producing plasma cells are frequently resistant to conventional immunosuppressive treatments and B-cell depletion therapy. As a result of this resistance, autoreactive plasma cells survive conventional therapy, resulting in persistent autoantibody production and inflammation. CD38 is hi...

Descripción completa

Detalles Bibliográficos
Autores principales: Frerichs, Kristine A., Verkleij, Christie P.M., Bosman, Patricia W.C., Zweegman, Sonja, Otten, Henny, van de Donk, Niels W.C.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388400/
https://www.ncbi.nlm.nih.gov/pubmed/32743508
http://dx.doi.org/10.1016/j.jtauto.2019.100022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388400/
https://www.ncbi.nlm.nih.gov/pubmed/32743508
http://dx.doi.org/10.1016/j.jtauto.2019.100022

Ejemplares similares